The primary endpoint , the mean reduction of average daily pain at week 12 compared with baseline , showed a positive dose-response relationship ( p = 0.014 , 1-sided ) ; the pair-wise comparison between the 10-mg group and placebo was significant ( unadjusted p = 0.040 , 2-sided ) .